protein

SLP 76 (LCP2, SLP76, SLP-76, lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kD), 76kD tyrosine phosphoprotein, SH2 domain-containing leukocyte protein of 76kD, lymphocyte cytosolic protein 2 (SH2 domain containing leuko

MBS658946

0.1 mg

400 USD

Peptide

SLP 76 (LCP2, SLP76, SLP-76, lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kD), 76kD tyrosine phosphoprotein, SH2 domain-containing leukocyte protein of 76kD, lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte p

[SLP 76]

[SLP 76 (LCP2, SLP76, SLP-76, lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kD), 76kD tyrosine phosphoprotein, SH2 domain-containing leukocyte protein of 76kD, lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte p]

[SLP-76; Lymphocyte cytosolic protein 2; lymphocyte cytosolic protein 2; 76 kDa tyrosine phosphoprotein; SLP-76 tyrosine phosphoprotein; SH2 domain-containing leukocyte protein of 76kD; SH2 domain-containing leukocyte protein of 76 kDa; lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa); SH2 domain-containing leukocyte protein of 76 kDa; SLP-76 tyrosine phosphoprotein]

[LCP2; LCP2; SLP76; SLP-76; SLP76]

LCP2_HUMAN

Recognizes human SLP76/LCP2

Supplied as a lyophilzed powder in ddH2O, 5% (v/v) acetonitrile. Reconstitute with 200ul sterile ddH2O.

~0.5mg/ml (after reconsitution)

Lyophilized powder may be stored at -20 degree C. Stable for 6 months at -20 degree C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. for maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be mad in assay buffer.

ELISA (EL/EIA), Antibody Blocking. Other applications not tested.

Suitable for use in ELISA and Antibody Blocking. Other applications not tested. Optimal dilutions to be determined by the researcher. ALRNVPFRSEV-C from the N-Terminus Control peptide corresponding to polyclonal antibody (Goat x Human). Peptide Blocking: Antibodies are typically supplied at 0.5mg/ml and peptides as a 100ul pellet. When peptides are reconstituted in 200ul water, the concentration would be also 0.5mg/ml. To start, the best ratio would be 1:1 (which means molar excess of peptides relative to antibodies when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots, to be incubated with equal amount of antibodies, but one with the antibodies pre-adsorbed to the peptide for 20 min. Then incubate and develop the two blots in parallel.

Source: Synthetic

Grade: Highly Purified

Molecular Biology; MB-T Cells

ALRNVPFRSEV-C from the N-Terminus

806766

AAC50135.1

Q13094

60,188 Da

Adaptive Immune System Pathway (366160); B Cell Receptor Signaling Pathway (198909); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550); FCERI Mediated Ca+2 Mobilization Pathway (833827); FCERI Mediated MAPK Activation Pathway (833826); Fc Epsilon RI Signaling Pathway (83082); Fc Epsilon RI Signaling Pathway (493); Fc Epsilon Receptor (FCERI) Signaling Pathway (833825); Fc-epsilon Receptor I Signaling In Mast Cells Pathway (138050)

SLP-76 was originally identified as a substrate of the ZAP-70 protein tyrosine kinase following T cell receptor (TCR) ligation in the leukemic T cell line Jurkat. The SLP-76 locus has been localized to human chromosome 5q33 and the gene structure has been partially characterized in mice. The human and murine cDNAs both encode 533 amino acid proteins that are 72% identical and comprised of three modular domains. The NH2-terminus contains an acidic region that includes a PEST domain and several tyrosine residues which are phosphorylated following TCR ligation. SLP-76 also contains a central proline-rich domain and a COOH-terminal SH2 domain. A number of additional proteins have been identified that associate with SLP-76 both constitutively and inducibly following receptor ligation, supporting the notion that SLP-76 functions as an adaptor or scaffold protein. Studies using SLP-76 deficient T cell lines or mice have provided strong evidence that SLP-76 plays a positive role in promoting T cell development and activation as well as mast cell and platelet function. [provided by RefSeq, Jul 2008]

Function: Involved in T-cell antigen receptor mediated signaling. Subunit structure: Interacts with SLA. Interacts with CBLB . By similarity. Interacts with the adapter proteins GRB2 and FYB. Interacts with SHB. Interacts with PRAM1. Ref.5 Ref.6. Subcellular location: Cytoplasm . Probable. Tissue specificity: Highly expressed in spleen, thymus and peripheral blood leukocytes. Highly expressed also in T-cell and monocytic cell lines, expressed at lower level in B-cell lines. Not detected in fibroblast or neuroblastoma cell lines. Domain: The SH2 domain mediates interaction with SHB. Post-translational modification: Phosphorylated after T-cell receptor activation by ZAP70, ITK and TXK, which leads to the up-regulation of Th1 preferred cytokine IL-2. SYK-dependent phosphorylation is required for recruitment of PI3K signaling components. Ref.8 Ref.10. Sequence similarities: Contains 1 SAM (sterile alpha motif) domain.Contains 1 SH2 domain.

0.1 mg

400 USD